News_BriSTAR

08.29 2025
Nature Medicine Publishes a Breakthrough! Experts highly praise A major step forward for off-the-shelf cell therapy in autoimmunity. Prof. Huji Xu, Prof. Xin Lin, and BriSTAR Immunotech are breaking new ground with YTS109, a hypoimmune allogeneic T cell product. Published in Nature Medicine:

08.28 2025
Landmark Study Published in Nature Medicine: BriSTAR Immunotech’s Allogeneic STAR-T Breaks New Ground in Refractory Lupus Nephritis Treatment On August 27, 2025, a groundbreaking study by BriSTAR Immunotech in collaboration with the team led by Professor Huji Xu and Professor Xin Lin , was published in the top international journal Nature Medicine (Impact Factor: 58.7).

11.18 2024
Professor Lin Xin's Team Publishes Landmark Research in Cell Sub-Journal: STAR-T Technology Enables Targeting of Intracellular Neoantigens for Solid Tumor Therapy Recently, a team led by Professor Xin Lin — Scientific Founder of Bristar Immunotech and Tenured Professor at Tsinghua University — published a research article titled "TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens" in Cell Reports, a sub-journal of Cell. This study demonstrates the high sensitivity of the novel chimeric antigen receptor STAR-T in targeting tumors with low-abundance neoantigens, promising to advance T-cell immunotherapy into an era of greater precision and efficacy. It also marks another breakthrough in STAR-T technology research.

03.23 2023
BriSTAR Immunotech to Present its Novel Cell Therapy for Acute Myeloid Leukemia at the 2023 AACR Annual Meeting March 23, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy platform at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

01.31 2023
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference January 31, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Marquis during February 6-9, 2023.

01.19 2023
BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS January 19, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.

09.19 2023
BriSTAR Immunotech Announces the Addition of Dr. Christopher J. Paige as a Member of the Company's Scientific Advisory Board On September 19, 2022 - TORONTO & BEIJING -- BriSTAR Immunotech announced that Dr. Christopher J. Paige, a world-renowned leader in the field of lymphocyte development and antibody formation and an expert in immunotherapy, has joined the company's Scientific Advisory Board.

01.15 2022
BriSTAR Immunotech Limited wins the KPMG China "First Top 50 Biotechnology Innovation Enterprises" Award 2022 On June 15, 2022, KPMG China releases the list of "the First Top 50 Biotechnology Innovation Enterprises 2022". With its excellent innovation strength and development potential, BriSTAR Immunotech Limited is successfully included into the list through screening and evaluation by KPMG China and industry experts after about 10 months.

10.11 2021
BriSTAR Immunotech Limited completed the round B financing of more than 200 million Yuan: Accelerating the Development of Innovative Cell Therapy Drugs for Meeting the Clinical Needs of the Patients with Advanced Cancer On October 11, 2021, BriSTAR Immunotech Limited announces that it has completed round B financing of more than RMB 200million in Beijing, China. This round of financing was led by the China Growth Capital.

06.17 2021
EHA 2021丨 BriSTAR Immunotech Limited releases the latest data on CD19/CD20 Dual STAR-T Therapy R/R B-ALL The articles come from eMedClub. The "Innovative CD 19/CD 20 Dual STAR-T Cell Therapy for the Treatment of Refractory/ Relapse (R/R) Acute B-Lymphocyte Leukemia (R/R B-ALL)" jointly launched by BrisSTAR Immunotech Limited with Ludaopei Hospital is honored to be one of the few studies selected in the special report of the EHA conference.